Efficacy and Safety of Akkermansia Muciniphila AKM Lab-01 for Overweight and Obesity

Официальное название

A Randomized, Double-blind, Placebo-controlled Trial to Access the Efficacy and Safety of Akkermansia Muciniphila AKM Lab-01 in Participents With Overweigh and Obesity

Обзор

This study is designed as a preliminary investigation to evaluate the weight-loss efficacy and safety of AKM Lab-01 in an overweight or obese population. It is an interventional, radomized, double-blind, placebo-controlled clinical trial. Participants who meet the eligibility criteria will be randomly assigned to receive AKM Lab-01 or a matching placebo. The intervention will be administered once daily for 3 months. Baseline metrics, along with blood, urine, and stool samples, will be collected from participants, before and after the AKM Lab-01 intervention. The analysis will focus on changes in body weight, blood lipids, blood glucose, and gut metagenomic profiles (from stool samples). Furthermore, metabolomic analysis of blood and stool samples will be conducted to explore the potential machanisms through which AMK Lab-01 influences body weight.

Вмешательства

• Препарат AKM Lab-01
  A specific dose of AKM Lab-01 will be administered orally once daily for a period of 3 months.
• Препарат Placebo
  Placebo will be administered orally once daily for a period of 3 months.

Первичные конечные точки

• Changes in BMI [Срок оценки: Baseline, Day 30, Day 60, Day 90]
• Changes in body weight [Срок оценки: Baseline, Day 30, Day 60, Day 90]

Вторичные конечные точки (5)

• Changes in TC [Срок оценки: Baseline, Day 90]
• Changes in HbA1c [Срок оценки: Baseline, Day 30, Day 90]
• Changes in Uric Acid [Срок оценки: Baseline, Day30, Day90]
• Changes in Blood Pressure [Срок оценки: Baseline, Day 30, Day 60, Day 90]
• Changes in LDL-C [Срок оценки: Baseline, Day 90]

Критерии участия

Критерии включения

• 1\) Age: 18-60 years old (inclusive); Gender: male or female.
• 2\) Body Mass Index (24.0≤BMI≤40.0 kg/m²).
• 3\) Has no taken any medications for metabolic control (e.g., for body weight, blood lipids, or blood glucose) within the past month.
• 4\) Has been attempting to manage weight primarily through lifestyle interventions (diet and exercise) for at least one month prior to screening.
• 5\) Processes adequate communication and cognitive abilities, is expected to be compliant with long-term medication, and has understood the nature, significance, potential benefits, inconveniences, and risks of the study prior to enrollment.
• 6\) For participants of childbearing potential (male or female): Must agree to use at least one medically approved form of contraception (e.g., intrauterine device \[IUD\], oral contraceptives, or condoms) throughout the trial. For female participants of childbearing potential: Must have a negative serum pregnancy test at screening and must be non-lactating.
• 7\) Voluntarily agrees to participate by signing the inform consent form and commits to follow the trial treatment plan and visit schedule.

Критерии исключения

• 1\) A clear history of neurological or psychiatric disorders (including epilepsy and dementia).
• 2\) Hyperlipidemia due to secondary causes, such as nephrotic syndrome, hepatic diseases, hypothyroidism, or renal failure.
• 3\) Concurrent severe medical conditions deemed by the investigator to require immediate treatment, such as severe diabetes mellitus, hypertriglyceridemia, or cerebrovascular disease.
• 4\) Concurrent severe primary diseases of the liver, kidney, or hematopoietic system; or individuals with mental illness.
• 5\) Participants with a family history of genetically inherited metabolic disorders.
• 6\) Participants currently taking hepatotropic medications.
• 7\) Participants with a history of prior bariatric surgery.
• 8\) Presence of poorly controlled or unstable acute/chronic diseases, including but not limited to:

• Cardiovascular diseases: Unstable angina, myocardial infarction within the past 6 months, symptomatic congestive heart failure (NYHA Class Ⅱ or higher), severe arrhythmia, ect.
• Uncontrolled active infectious diseases, malignancies, ect.
• 9\) Participants with hepatic or renal insufficiency, defined as:

• Alanine aminotransferase (ALT) or Aspartate aminotransferase (AST) > 2.5 × ULN (Upper Limit of Normal);
• Serum total bilirubin > 2.5 × ULN;
• Creatinine (Cr) > 1.5 × ULN.
• 10\) Urine amylase ≥ 1.5 × ULN, or any other laboratory abnormality deemed by the investigator to be clinically significant and incompatible with study participation.
• 11\) History of acute diabetic complications (e.g., diabetic ketoacidosis or hyperosmolar hyperglycemic state) within the past 3 months.
• 12\) History of gastrointestinal surgery within the past year, or the presence of severe, active gastrointestinal disease that is not stabilized and may affect drug absorption, distribution, metabolism, or excretion.
• 13\) Know hypersensitivity or allergy to any active ingredient or excipient of the investigational product.
• 14\) Use of antibiotic therapy or intake of probiotics/prebiotic supplements within 3 month prior to screening.
• 15\) Excessive alcohol consumption (defined as > 30 grams per day for men or > 20 gram, sraems) with the past 10 years.
• 16\) pregnant or lactating women.
• 17\) Any other medical condition that, in the judgement of the investigator, may put the participant at increased or be aggravated by participation in the study. The specific reason for exclusion based on this criterion must be documented.

Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.

Здоровые добровольцы: Нет

Дизайн исследования

Распределение

Рандомизированное

Модель

Параллельные группы

Маскирование

Тройное слепое

Основная цель

Лечение

Центры проведения

Китай · 1 центр

• Guangzhou Huangpu District People's Hospital — Гуанчжоу

Идентификаторы

NCT: NCT07331974 · MN-AKM-102

Первоисточники (государственные реестры)

• ClinicalTrials.gov (NIH, США)

Открыть это исследование на ClinicalTrials.gov ↗